Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy

Duan Ni, Jiacheng Wei, Xinheng He, Ashfaq Ur Rehman, Xinyi Li, Yuran Qiu, Jun Pu, Shaoyong Lu and Jian Zhang

Chem. Sci., 2021, 12, 464
DOI: 10.1039/D0SC05131D

In vitro and in silico hybrid approach to unveil triterpenoids from Helicteres hirsuta leaves as potential compounds for inhibiting Nrf2

Minh Hien Nguyen, Nguyen Thien Han Le, Bui Quoc Huy Nguyen, Mai Thanh Thi Nguyen, Truong Nhat Van Do, Tho Huu Le, Vu Thanh Nguyen and Chia-Hung Yen

RSC Adv., 2025, 15, 1915
DOI: 10.1039/D4RA07646J

The allosteric mechanism of mTOR activation can inform bitopic inhibitor optimization

Yonglan Liu, Mingzhen Zhang, Hyunbum Jang and Ruth Nussinov

Chem. Sci., 2024, 15, 1003
DOI: 10.1039/D3SC04690G

Synthesis of 2-trifluoromethyl thiazoles via [3 + 2] cycloaddition of pyridinium 1,4-zwitterionic thiolates with CF3CN

Yunfei Yao, Bo Lin, Minze Wu, Yafang Zhang, Yangjie Huang, Xiaoyan Han and Zhiqiang Weng

Org. Biomol. Chem., 2022, 20, 8761
DOI: 10.1039/D2OB01749K

A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα

Werner Theodor Jauslin, Matthias Schild, Thorsten Schaefer, Chiara Borsari, Clara Orbegozo, Lukas Bissegger, Saule Zhanybekova, Danilo Ritz, Alexander Schmidt, Matthias Wymann and Dennis Gillingham

Chem. Sci., 2024, 15, 683
DOI: 10.1039/D3SC04629J

Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity

Sarah Christine Elisabeth Wright, Natali Vasilevski, Violeta Serra, Jordi Rodon and Pieter Johan Adam Eichhorn

Cancers, 2021, 13, 1538
DOI: 10.3390/cancers13071538

Design of Novel Phosphatidylinositol 3-Kinase Inhibitors for Non-Hodgkin’s Lymphoma: Molecular Docking, Molecular Dynamics, and Density Functional Theory Studies on Gold Nanoparticles

Abdalrahim M. Ali, Alaa A. Makki, Walaa Ibraheem, Mohammed Abdelrahman, Wadah Osman, Asmaa E. Sherif, Ahmed Ashour, Sabrin R. M. Ibrahim, Kholoud F. Ghazawi, Waad A. Samman and Abdulrahim A. Alzain

Molecules, 2023, 28, 2289
DOI: 10.3390/molecules28052289

Cordycepin ameliorates spaceflight-induced osteoporosis by preventing BMSCs oxidative stress and senescence via interacting with PI3K p110α and regulating PI3K/Akt/FOXO3 signalling

Yu Zhai, Yuyao Zhang, Kexin Xu, Tianling Wang, Zhiqun Bian, Langfan Qu, Feng Wu, Zhilei Hu, Xian Chang, Haiyin Li, Chao Zhang, Changqing Li and Chunmeng Shi

Free Radical Biology and Medicine, 2025, 228, 108
DOI: 10.1016/j.freeradbiomed.2024.12.044

Structural insights into isoform-specific RAS-PI3Kα interactions and the role of RAS in PI3Kα activation

Daniel Czyzyk, Wupeng Yan, Simon Messing, William Gillette, Takashi Tsuji, Mitsuhiro Yamaguchi, Shinji Furuzono, David M. Turner, Dominic Esposito, Dwight V. Nissley, Frank McCormick and Dhirendra K. Simanshu

Nat Commun, 2025, 16
DOI: 10.1038/s41467-024-55766-x

Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside

Icro Meattini, Lorenzo Livi, Nicla Lorito, Carlotta Becherini, Marina Bacci, Luca Visani, Alessandra Fozza, Liliana Belgioia, Mauro Loi, Monica Mangoni, Matteo Lambertini and Andrea Morandi

Cancer Treatment Reviews, 2022, 108, 102417
DOI: 10.1016/j.ctrv.2022.102417

A novel iheyamine A derivative L42 suppresses acute myeloid leukemia via dual regulation of the PI3K/AKT/FOXO3a axis and TNF signaling pathway

Wang Dinghuan, Kuang Yi, Tian Jianzhi, Wei Wenfei, Wang Chunlin, Hu Anling, He Zhixu, Yaacov Ben-David, Liu Sheng, Yang Xiaoyan and Xiao Xiao

Biomedicine & Pharmacotherapy, 2024, 177, 117071
DOI: 10.1016/j.biopha.2024.117071

Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway

Xingchen Li, Guidong Chen, Fanchen Wang, Xiaojing Guo, Rui Zhang, Pengpeng Liu, Li Dong, Wenwen Yu, Huan Wang, Hailong Wang and Jinpu Yu

Clinical & Translational Med, 2023, 13
DOI: 10.1002/ctm2.1483

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)

Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel and Haizhen A. Zhong

Expert Opinion on Therapeutic Patents, 2021, 31, 877
DOI: 10.1080/13543776.2021.1924150

CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets

Wengang Zhang, Yonglan Liu, Hyunbum Jang and Ruth Nussinov

JACS Au, 2024, 4, 1911
DOI: 10.1021/jacsau.4c00138

Harnessing Reversed Allosteric Communication: A Novel Strategy for Allosteric Drug Discovery

Jigang Fan, Yaqin Liu, Ren Kong, Duan Ni, Zhengtian Yu, Shaoyong Lu and Jian Zhang

J. Med. Chem., 2021, 64, 17728
DOI: 10.1021/acs.jmedchem.1c01695

CBF-Beta Mitigates PI3K-Alpha–Specific Inhibitor Killing through PIM1 in PIK3CA-Mutant Gastric Cancer

Lyla J. Stanland, Hazel X. Ang, Jacob P. Hoj, Yunqiang Chu, Patrick Tan, Kris C. Wood and Micah A. Luftig

Molecular Cancer Research, 2023, 21, 1148
DOI: 10.1158/1541-7786.MCR-23-0034

Binding Modalities and Phase-Specific Regulation of Cyclin/Cyclin-Dependent Kinase Complexes in the Cell Cycle

Michael T. Bergman, Wengang Zhang, Yonglan Liu, Hyunbum Jang and Ruth Nussinov

J. Phys. Chem. B, 2024, 128, 9315
DOI: 10.1021/acs.jpcb.4c03243

Review: The PI3K-AKT-mTOR signal transduction pathway in canine cancer

Travis K. Meuten, Gregg A. Dean and Douglas H. Thamm

Vet Pathol, 2024, 61, 339
DOI: 10.1177/03009858231207021

Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition

Mei Li, Daoping Wang, Qing Li, Fang Luo, Ting Zhong, Hongshan Wu, Liang Xiong, Meitao Yuan, Mingzhi Su and Yanhua Fan

IJMS, 2023, 24, 6851
DOI: 10.3390/ijms24076851

Two binuclear copper(II) complexes incorporated with 3-phenylpentanedioic acid: crystal structure and bioactivity characteristics

Ren-Shu Wang, Jing Feng, Ping Zhang, Hu Wang and Yi-Zhu Lei

Res Chem Intermed, 2023, 49, 5121
DOI: 10.1007/s11164-023-05086-4

Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein

Zhen Wah Tan, Wei-Ven Tee, Firdaus Samsudin, Enrico Guarnera, Peter J. Bond and Igor N. Berezovsky

Structure, 2022, 30, 590
DOI: 10.1016/j.str.2021.12.011

Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer

Motahareh Mortazavi, Fatemeh Moosavi, Miriam Martini, Elisa Giovannetti and Omidreza Firuzi

Critical Reviews in Oncology/Hematology, 2022, 176, 103749
DOI: 10.1016/j.critrevonc.2022.103749

Discovery of a Novel Photocaged PI3K Inhibitor Capable of Real-Time Reporting of Drug Release

Hua Tian, Shen You, Tianning Xiong, Ming Ji, Kehui Zhang, Lin Jiang, Tingting Du, Ying Li, Wenqian Liu, Songwen Lin, Xiaoguang Chen and Heng Xu

ACS Med. Chem. Lett., 2023, 14, 1100
DOI: 10.1021/acsmedchemlett.3c00240

Isoform-selective targeting of PI3K: time to consider new opportunities?

Davide Cirillo, Marta Diceglie and Marc Nazaré

Trends in Pharmacological Sciences, 2023, 44, 601
DOI: 10.1016/j.tips.2023.06.002

Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer

Le Yu, Jessica Wei and Pengda Liu

Seminars in Cancer Biology, 2022, 85, 69
DOI: 10.1016/j.semcancer.2021.06.019

Network pharmacology and molecular docking study to reveal the potential anticancer activity of Oscillatoxin D, E, and F marine cytotoxins

D. Luthfiana, M. Soleha, A. Prasetiyo, W. A. Kusuma, R. Fatriani, L. Nurfadhila, N. Yunitasari, A. H. Ahkam, T. L. Wargasetia, R. Irfandi, A. N. M. Ansori, V. D. Kharisma, S. W. Naw, E. Ullah, V. Jakhmola and R. Zainul

Food systems, 2023, 6, 365
DOI: 10.21323/2618-9771-2023-6-3-365-389

Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes

Zihan Zhou, Peifeng Li, Xianbin Zhang, Juan Xu, Jin Xu, Shui Yu, Dongqing Wang, Wei Dong, Xiujuan Cao, Hongjiang Yan, Mingping Sun, Xiuping Ding, Jun Xing, Peng Zhang, Limin Zhai, Tingyong Fan, Shiyu Tian, Xinhua Yang and Man Hu

Mol Med, 2022, 28
DOI: 10.1186/s10020-022-00479-4

PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN

Xiaodan Chong, Jingde Chen, Nanxin Zheng, Zhuqing Zhou, Yanan Hai, Shiqing Chen, Yu Zhang, Qingzhuo Yu, Shijun Yu, Zhiqin Chen, Wenfang Bao, Ming Quan, Zhe-Sheng Chen, Yangyang Zhan and Yong Gao

Mol Cancer, 2022, 21
DOI: 10.1186/s12943-022-01531-x

Application of network pharmacology, bioinformatics, computational molecular docking, and experimental validation to study the anticancer effects of oleanolic acid in oral squamous carcinoma cells

Ting Yin, Hao Wang and Yaqin Zou

Acta Pharmaceutica, 2025, 75, 41
DOI: 10.2478/acph-2025-0005

Ras, RhoA, and vascular pharmacology in neurodevelopment and aging

Ruth Nussinov, Hyunbum Jang and Feixiong Cheng

Neurochemistry International, 2024, 181, 105883
DOI: 10.1016/j.neuint.2024.105883

Ras isoform-specific expression, chromatin accessibility, and signaling

Ruth Nussinov, Mingzhen Zhang, Ryan Maloney and Hyunbum Jang

Biophys Rev, 2021, 13, 489
DOI: 10.1007/s12551-021-00817-6

Liquid biopsy: Cell-free DNA based analysis in breast cancer

Konstantinos Venetis, Giulia Cursano, Carlo Pescia, Marianna D'Ercole, Francesca Maria Porta, Marta Cruz Blanco, Chiara Frascarelli, Mariia Ivanova, Elena Guerini Rocco and Nicola Fusco

The Journal of Liquid Biopsy, 2023, 1, 100002
DOI: 10.1016/j.jlb.2023.100002

Mechanism of activation and the rewired network: New drug design concepts

Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, Chung‐Jung Tsai, Bengi Ruken Yavuz, Nurcan Tuncbag and Hyunbum Jang

Medicinal Research Reviews, 2022, 42, 770
DOI: 10.1002/med.21863

Identification of Multi-kinase Allosteric Inhibitors of Oncogenic Targets EGFR1, PI3K, and BRAF Kinase

Kavita Kumari Kakarala and Kaiser Jamil

CAD, 2022, 18, 506
DOI: 10.2174/1573409919666221031110341

Novel Therapies and Emerging Actives for Treatment of Luminal Breast Cancer

Preeti Tanaji Mane, Balaji Sopanrao Wakure and Pravin Shridhar Wakte

RJPT, 2023, 5522
DOI: 10.52711/0974-360X.2023.00893

Synthesis of Novel 2,9-Disubstituted-6-morpholino Purine Derivatives Assisted by Virtual Screening and Modelling of Class I PI3K Isoforms

Vítor Lobo, Ashly Rocha, Tarsila G. Castro and Maria Alice Carvalho

Polymers, 2023, 15, 1703
DOI: 10.3390/polym15071703

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Daolin Tang, Guido Kroemer and Rui Kang

Mol Cancer, 2021, 20
DOI: 10.1186/s12943-021-01422-7

Pharmacological tools to investigate inositol polyphosphate kinases – Enzymes of increasing therapeutic relevance

Tim Kröber, Simon M. Bartsch and Dorothea Fiedler

Advances in Biological Regulation, 2022, 83, 100836
DOI: 10.1016/j.jbior.2021.100836

Pioneer in Molecular Biology: Conformational Ensembles in Molecular Recognition, Allostery, and Cell Function

Ruth Nussinov

Journal of Molecular Biology, 2025, 437, 169044
DOI: 10.1016/j.jmb.2025.169044

Mechanistic Insights Into Co-Administration of Allosteric and Orthosteric Drugs to Overcome Drug-Resistance in T315I BCR-ABL1

Hao Zhang, Mingsheng Zhu, Mingzi Li, Duan Ni, Yuanhao Wang, Liping Deng, Kui Du, Shaoyong Lu, Hui Shi and Chen Cai

Front. Pharmacol., 2022, 13
DOI: 10.3389/fphar.2022.862504

Network pharmacology-based approach uncovers the pharmacodynamic components and mechanism of Fructus Tribuli for improving endothelial dysfunction in hypertension

Shu-Yue Wang, Xiao-Chen Sun, Xi-Yu Lv, Jing-Na Li, Bing Han, Kun-Lin Liu, Shuai Wang, Hua-Gang Sheng, Chao Zhang, Fei Guo and Yi-Dong Cui

Journal of Ethnopharmacology, 2023, 316, 116749
DOI: 10.1016/j.jep.2023.116749

Development of PI3K inhibitors: Advances in clinical trials and new strategies (Review)

Dandan Meng, Wei He, Yan Zhang, Zhenguo Liang, Jinling Zheng, Xu Zhang, Xing Zheng, Peng Zhan, Hongfei Chen, Wenjun Li and Lintao Cai

Pharmacological Research, 2021, 173, 105900
DOI: 10.1016/j.phrs.2021.105900

Computational Modeling of Novel Phosphoinositol‐3‐kinase γ Inhibitors Using Molecular Docking, Molecular Dynamics, and 3D‐QSAR

Suparna Ghosh, Seketoulie Keretsu and Seung Joo Cho

Bulletin Korean Chem Soc, 2021, 42, 1093
DOI: 10.1002/bkcs.12305

Heparin/Collagen-REDV Modification of Expanded Polytetrafluoroethylene Improves Regional Anti-thrombosis and Reduces Foreign Body Reactions in Local Tissues

Yaping Shan, Gang Chen, Qiqi Shi, Jiaxi Huang, Yaping Mi, Wenbo Zhang, Huifeng Zhang and Bing Jia

Front. Bioeng. Biotechnol., 2022, 10
DOI: 10.3389/fbioe.2022.916931

The emerging role of PI3K inhibitors for solid tumour treatment and beyond

Carmen Belli, Matteo Repetto, Santosh Anand, Camillo Porta, Vivek Subbiah and Giuseppe Curigliano

Br J Cancer, 2023, 128, 2150
DOI: 10.1038/s41416-023-02221-1

Anticancer drugs: How to select small molecule combinations?

Ruth Nussinov, Bengi Ruken Yavuz and Hyunbum Jang

Trends in Pharmacological Sciences, 2024, 45, 503
DOI: 10.1016/j.tips.2024.04.012

Advances in 2‐substituted benzothiazole scaffold‐based chemotherapeutic agents

Kashif Haider, Sara Rehman, Ankita Pathak, Abul K. Najmi and Mohammad S. Yar

Archiv der Pharmazie, 2021, 354
DOI: 10.1002/ardp.202100246

Tumors and their microenvironments: Learning from pediatric brain pathologies

Ruth Nussinov, Bengi Ruken Yavuz and Hyunbum Jang

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025, 1880, 189328
DOI: 10.1016/j.bbcan.2025.189328

Current and Future Therapeutic Targets: A Review on Treating Head and Neck Squamous Cell Carcinoma

Geet Madhukar and Naidu Subbarao

CCDT, 2021, 21, 386
DOI: 10.2174/1568009620666201229120332

Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer

Huayi Li, Lorenzo Prever, Emilio Hirsch and Federico Gulluni

Cancers, 2021, 13, 3517
DOI: 10.3390/cancers13143517

Identifying Active Compounds and Mechanisms of Citrus changshan-Huyou Y. B. Chang against URTIs-Associated Inflammation by Network Pharmacology in Combination with Molecular Docking

Shiyi Chen, Wenkang Huang, Xiaoyu Li, Lijuan Gao, Yiping Ye and Smail Aazza

Evidence-Based Complementary and Alternative Medicine, 2022, 2022, 1
DOI: 10.1155/2022/2156157

Hybridization-based discovery of novel quinazoline-2-indolinone derivatives as potent and selective PI3Kα inhibitors

Changqun Liu, Yuening Cao, Yi Zuo, Chaozheng Zhang, Senmiao Ren, Xin Zhang, Chuanqi Wang, Yingjie Zeng, Jie Ling, Yilan Liu, Zixian Chen, Xiujun Cao, Zhengzhi Wu, Chuantao Zhang and Jun Lu

Journal of Advanced Research, 2025, 68, 459
DOI: 10.1016/j.jare.2024.03.002

Inhibition of Nonfunctional Ras

Ruth Nussinov, Hyunbum Jang, Attila Gursoy, Ozlem Keskin and Vadim Gaponenko

Cell Chemical Biology, 2021, 28, 121
DOI: 10.1016/j.chembiol.2020.12.012

Role of Molecular Targeted Therapeutic Drugs in Treatment of Breast Cancer: A Review Article

Himanshu Singh

Glob Med Genet, 2023, 10, 079
DOI: 10.1055/s-0043-57247

Exploring the Allosteric Territory of Protein Function

Wei-Ven Tee, Zhen Wah Tan, Keene Lee, Enrico Guarnera and Igor N. Berezovsky

J. Phys. Chem. B, 2021, 125, 3763
DOI: 10.1021/acs.jpcb.1c00540

Pyrrolotriazinone as an Underexplored Scaffold in Drug Discovery

Tony Ge and Jean-Christophe Cintrat

Pharmaceuticals, 2021, 14, 1275
DOI: 10.3390/ph14121275

A deep learning-based theoretical protocol to identify potentially isoform-selective PI3Kα inhibitors

Muhammad Shafiq, Zaid Anis Sherwani, Mamona Mushtaq, Mohammad Nur-e-Alam, Aftab Ahmad and Zaheer Ul-Haq

Mol Divers, 2024, 28, 1907
DOI: 10.1007/s11030-023-10799-0

Current developments in PI3K-based anticancer agents: Designing strategies, biological activity, selectivity, structure-activity correlation, and docking insight

Md. Ashadul Sk, Hemalatha K., Gurubasavaraja Swamy Purawarga Matada, Rohit Pal, Manjushree B.V., S. Mounika, Haripriya E., Viji M.P. and Anjan D.

Bioorganic Chemistry, 2025, 154, 108011
DOI: 10.1016/j.bioorg.2024.108011

The orchestrated signaling by PI3Kα and PTEN at the membrane interface

Danai Maria Kotzampasi, Kyriaki Premeti, Alexandra Papafotika, Vasiliki Syropoulou, Savvas Christoforidis, Zoe Cournia and George Leondaritis

Computational and Structural Biotechnology Journal, 2022, 20, 5607
DOI: 10.1016/j.csbj.2022.10.007

Anticancer drug resistance: An update and perspective

Ruth Nussinov, Chung-Jung Tsai and Hyunbum Jang

Drug Resistance Updates, 2021, 59, 100796
DOI: 10.1016/j.drup.2021.100796

Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

Muhammad Tufail, Jia-Ju Hu, Jie Liang, Cai-Yun He, Wen-Dong Wan, Yu-Qi Huang, Can-Hua Jiang, Hong Wu and Ning Li

J Transl Med, 2024, 22
DOI: 10.1186/s12967-023-04841-w

Design, synthesis, and anticancer evaluation of N6‐hydrazone purine derivatives with potential antiplatelet aggregation activity

Chaochun Wei, Liying Zhou, Yifan Yang, Lexuan Niu and Hong Yan

Chem Biol Drug Des, 2023, 101, 568
DOI: 10.1111/cbdd.14145

Polymeric Nanoparticles Potentiate the Anticancer Activity of Novel PI3Kα Inhibitors Against Triple-Negative Breast Cancer Cells

Suhair Sunoqrot, Samah Abusulieh and Dima Sabbah

Biomedicines, 2024, 12, 2676
DOI: 10.3390/biomedicines12122676

Development of PI3Kα inhibitors for tumor therapy

Wenqing Jia, Shuyu Luo, Han Guo and Dexin Kong

Journal of Biomolecular Structure and Dynamics, 2023, 41, 8587
DOI: 10.1080/07391102.2022.2132293

Induced proximity tools for precise manipulation of lipid signaling

Reika Tei and Jeremy M. Baskin

Current Opinion in Chemical Biology, 2021, 65, 93
DOI: 10.1016/j.cbpa.2021.06.005

VASP, HCLS1, MSN, and EZR: Key molecular beacons in the pathophysiology of perihematomal edema Post-Intracerebral hemorrhage

Jingjing Chen, Yi Zhong, Xueshun Xie, Guannan Jiang, Lei Bai, Haiying Li, Xiang Li, Ximing Wang and Gang Chen

Brain Hemorrhages, 2024, 5, 223
DOI: 10.1016/j.hest.2024.04.002

The value of protein allostery in rational anticancer drug design: an update

Ruth Nussinov and Hyunbum Jang

Expert Opinion on Drug Discovery, 2024, 19, 1071
DOI: 10.1080/17460441.2024.2384467

Allostery in Disease: Anticancer Drugs, Pockets, and the Tumor Heterogeneity Challenge

Ruth Nussinov, Bengi Ruken Yavuz and Hyunbum Jang

Journal of Molecular Biology, 2025, 169050
DOI: 10.1016/j.jmb.2025.169050

The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia

Yonglan Liu, Hyunbum Jang, Mingzhen Zhang, Chung-Jung Tsai, Ryan Maloney and Ruth Nussinov

Biophysical Journal, 2022, 121, 2251
DOI: 10.1016/j.bpj.2022.05.030

Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer

Muhammad Tufail, Wen-Dong Wan, Canhua Jiang and Ning Li

Chemico-Biological Interactions, 2024, 396, 111055
DOI: 10.1016/j.cbi.2024.111055

AlphaFold, allosteric, and orthosteric drug discovery: Ways forward

Ruth Nussinov, Mingzhen Zhang, Yonglan Liu and Hyunbum Jang

Drug Discovery Today, 2023, 28, 103551
DOI: 10.1016/j.drudis.2023.103551

The protective mechanism of Dehydromiltirone in diabetic kidney disease is revealed through network pharmacology and experimental validation

Yanzhe Wang, Yuyuan Liu, Sijia Chen, Fengqin Li, Yue Wu, Xinmiao Xie, Nan Zhang, Chuchu Zeng, Linnan Bai, Mengshi Dai, Ling Zhang and Xiaoxia Wang

Front. Pharmacol., 2023, 14
DOI: 10.3389/fphar.2023.1201296

Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol‐3‐kinase (PI3K): Current and Future Prospects

Daniel A. Rodrigues, Pedro S. M. Pinheiro and Carlos A. M. Fraga

ChemMedChem, 2021, 16, 448
DOI: 10.1002/cmdc.202000643

Multi-targeted HDAC Inhibitors as Anticancer Agents: Current Status and Future Prospective

Vijay K. Patel, Ekta Shirbhate, Priya Tiwari, Rakesh Kore, Ravichandran Veerasamy, Achal Mishra and Harish Rajak

CMC, 2023, 30, 2762
DOI: 10.2174/0929867329666220922105615

Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options

Constanze Elfgen and Vesna Bjelic-Radisic

Cancers, 2021, 13, 5994
DOI: 10.3390/cancers13235994

A comprehensive review on phosphatidylinositol-3-kinase (PI3K) and its inhibitors bearing pyrazole or indazole core for cancer therapy

Inês M. Bastos, Sandra Rebelo and Vera L.M. Silva

Chemico-Biological Interactions, 2024, 398, 111073
DOI: 10.1016/j.cbi.2024.111073

RAS‐targeted cancer therapy: Advances in drugging specific mutations

Cen Liu, Danyang Ye, Hongliu Yang, Xu Chen, Zhijun Su, Xia Li, Mei Ding and Yonggang Liu

MedComm, 2023, 4
DOI: 10.1002/mco2.285

Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

Andreas Varkaris, Ferran Fece de la Cruz, Elizabeth E. Martin, Bryanna L. Norden, Nicholas Chevalier, Allison M. Kehlmann, Ignaty Leshchiner, Haley Barnes, Sara Ehnstrom, Anastasia-Maria Stavridi, Xin Yuan, Janice S. Kim, Haley Ellis, Alkistis Papatheodoridi, Hakan Gunaydin, Brian P. Danysh, Laxmi Parida, Ioannis Sanidas, Yongli Ji, Kayao Lau, Gerburg M. Wulf, Aditya Bardia, Laura M. Spring, Steven J. Isakoff, Jochen K. Lennerz, Kathryn Del Vecchio, Levi Pierce, Ermira Pazolli, Gad Getz, Ryan B. Corcoran and Dejan Juric

Cancer Discovery, 2024, 14, 227
DOI: 10.1158/2159-8290.CD-23-0704

Zirconium Hydride Catalysis Initiated by Tetrabutylammonium Fluoride

Athenea N. Aloiau, Briana M. Bobek, Kelly E. Pearson, Kendall E. Cherry, Christopher R. Smith, John M. Ketcham, Matthew A. Marx and Stephen J. Harwood

J. Org. Chem., 2024, 89, 11525
DOI: 10.1021/acs.joc.4c01227

Structural Features that Distinguish Inactive and Active PI3K Lipid Kinases

Mingzhen Zhang, Hyunbum Jang and Ruth Nussinov

Journal of Molecular Biology, 2020, 432, 5849
DOI: 10.1016/j.jmb.2020.09.002

The effects of PIK3CA mutations on cervical cancer

Yuyi Zhang and E.-S. Salama

E3S Web of Conf., 2024, 553, 05025
DOI: 10.1051/e3sconf/202455305025

Development of some derivatives of pyrimidine-5-carbonitrile as inhibitors of PI3K and screening of their anticancer activity

Nada A. Edris, Hanan H. Kadry, Azza T. Taher, Ahmed A. El-Rashedy and Mina E. Adly

Journal of Molecular Structure, 2025, 1334, 141724
DOI: 10.1016/j.molstruc.2025.141724

Predict the Drug–Drug Interaction of a Novel PI3Kα/δ Inhibitor, TQ‐B3525, and Its Two Metabolites Using Physiologically Based Pharmacokinetic Modeling

Shixing Zhu, Ding Yu, Xunqiang Wang and Xin Wang

The Journal of Clinical Pharma, 2024, 64, 1517
DOI: 10.1002/jcph.6111

Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs

Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, Yonglan Liu, Chung-Jung Tsai and Hyunbum Jang

Journal of Molecular Biology, 2022, 434, 167569
DOI: 10.1016/j.jmb.2022.167569

The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane

Hyunbum Jang, Iris Nira Smith, Charis Eng and Ruth Nussinov

iScience, 2021, 24, 102438
DOI: 10.1016/j.isci.2021.102438

Targeting the PI3K/AKT/mTOR Signaling Pathway in the Treatment of Human Diseases: Current Status, Trends, and Solutions

Jindi Huang, Liye Chen, Jiangxia Wu, Daiqiao Ai, Ji-Quan Zhang, Tie-Gen Chen and Ling Wang

J. Med. Chem., 2022, 65, 16033
DOI: 10.1021/acs.jmedchem.2c01070

New and Emerging Targeted Therapies for Advanced Breast Cancer

Kristie H. Lau, Alexandra M. Tan and Yihui Shi

IJMS, 2022, 23, 2288
DOI: 10.3390/ijms23042288

Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges

Jan Rataj, Lukas Gorecki, Darina Muthna, Ales Sorf, Vladimir Krystof, Pavel Klener, Martina Ceckova, Martina Rezacova and Jan Korabecny

Biomedicine & Pharmacotherapy, 2025, 182, 117788
DOI: 10.1016/j.biopha.2024.117788

Along the allostery stream: Recent advances in computational methods for allosteric drug discovery

Duan Ni, Zongtao Chai, Ying Wang, Mingyu Li, Zhengtian Yu, Yaqin Liu, Shaoyong Lu and Jian Zhang

WIREs Comput Mol Sci, 2022, 12
DOI: 10.1002/wcms.1585

An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer

Hephzibah Cathryn R., Udhaya Kumar S., Gnanasambandan R., P. Jeyaprakash Naayanan, P. Sathiyarajeswaren, M. S. Shree Devi, Satish Srinivas K. and George Priya Doss C.

J of Cellular Biochemistry, 2023, 124, 188
DOI: 10.1002/jcb.30354

Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand-based pharmacophores and biological screening

Mahmoud A. Al-Sha’er, Mutasem Taha and Mahmoud A. Alelaimat

Med Chem Res, 2023, 32, 1109
DOI: 10.1007/s00044-023-03057-3

Efectos secundarios oculares de las terapias oncológicas. Revisión

M. Asencio-Durán, E. Fernández-Gutiérrez, M. Larrañaga-Cores, C. Klein-Burgos, J.V. Dabad-Moreno and M. Capote-Díez

Archivos de la Sociedad Española de Oftalmología, 2024, 99, 109
DOI: 10.1016/j.oftal.2023.09.008

Anticancer properties of chimeric HDAC and kinase inhibitors

Bernhard Biersack, Sibel Polat and Michael Höpfner

Seminars in Cancer Biology, 2022, 83, 472
DOI: 10.1016/j.semcancer.2020.11.005

Design, Synthesis and Phenotypic Profiling of Simplified Gedatolisib Analogues

Caroline Marques Xavier Costa, Cristiane Aparecida-Silva, Luis Eduardo Reina Gamba, Thalita Neves de Melo, Gisele Barbosa, Manoel Oliveira de Moraes Junior, Victoria Regina Thomaz de Oliveira, Carolinne Souza de Amorim, João A. Moraes, Eliezer Jesus Barreiro and Lídia Moreira Lima

Pharmaceuticals, 2023, 16, 209
DOI: 10.3390/ph16020209

Drug discovery by targeting the protein–protein interactions involved in autophagy

Honggang Xiang, Mi Zhou, Yan Li, Lu Zhou and Renxiao Wang

Acta Pharmaceutica Sinica B, 2023, 13, 4373
DOI: 10.1016/j.apsb.2023.07.016

Learning About Allosteric Drugs and Ways to Design Them

Zhen Wah Tan, Wei-Ven Tee and Igor N. Berezovsky

Journal of Molecular Biology, 2022, 434, 167692
DOI: 10.1016/j.jmb.2022.167692

In silico discovery of a novel potential allosteric PI3Kα inhibitor incorporating 2-oxopropyl urea targeting head and neck squamous cell carcinoma

Wenqing Jia, Guangzhuang Li, Xianchao Cheng, Ruijie Zhang and Yukui Ma

BMC Chemistry, 2025, 19
DOI: 10.1186/s13065-025-01420-6

Ocular side effects of oncological therapies: Review

M. Asencio-Durán, E. Fernández-Gutiérrez, M. Larrañaga-Cores, C. Klein-Burgos, J.V. Dabad-Moreno and M. Capote-Díez

Archivos de la Sociedad Española de Oftalmología (English Edition), 2024, 99, 109
DOI: 10.1016/j.oftale.2023.11.003

Repurposing inhibitors of phosphoinositide 3-kinase as adjuvant therapeutics for bacterial infections

Renee Fleeman

Front. Antibiot., 2023, 2
DOI: 10.3389/frabi.2023.1135485

Synthetic Methodologies and SAR of Quinazoline Derivatives as PI3K Inhibitors

Aditya Raj, Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, Suresh Thareja and Pradeep Kumar

ACAMC, 2023, 23, 1013
DOI: 10.2174/1871520623666230116163424

First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu, Hong-Yun Zhao, Yang Zhang, Zhi-Qiang Wang, Miao-Zhen Qiu, Fei Xu, Qiu-Qiong Yu, Yi-Wu Du, Yan-Xia Shi, De-Sheng Wang, Feng-Hua Wang and Rui-Hua Xu

Nat Commun, 2022, 13
DOI: 10.1038/s41467-022-34782-9

Role of tumor-derived exosomes mediated immune cell reprograming in cancer

Zening Liu, Zichao Chen, Jing Zhang, Junqiu Liu, Baohong Li, Zhenyong Zhang, Meichao Cai and Zhen Zhang

Gene, 2024, 925, 148601
DOI: 10.1016/j.gene.2024.148601

Alpelisib to treat CLOVES syndrome, a member of the PIK3CA‐related overgrowth syndrome spectrum

Gemma Garreta Fontelles, Júlia Pardo Pastor and Carme Grande Moreillo

Brit J Clinical Pharma, 2022, 88, 3891
DOI: 10.1111/bcp.15270

Design, Synthesis, Biological Evaluation, and Computational Studies of Novel Fluorinated Candidates as PI3K Inhibitors: Targeting Fluorophilic Binding Sites

Ahmed H. Tantawy, Mohammed Farrag El-Behairy, Walaa Hamada Abd-Allah, Hong Jiang, Man-Qun Wang and Adel A. Marzouk

J. Med. Chem., 2021, 64, 17468
DOI: 10.1021/acs.jmedchem.1c01674

The Importance of Being PI3K in the RAS Signaling Network

Cristina Cuesta, Cristina Arévalo-Alameda and Esther Castellano

Genes, 2021, 12, 1094
DOI: 10.3390/genes12071094

PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective

Mingzhen Zhang, Hyunbum Jang and Ruth Nussinov

Cancer Research, 2021, 81, 237
DOI: 10.1158/0008-5472.CAN-20-0911

Strategy toward Kinase-Selective Drug Discovery

Mingzhen Zhang, Yonglan Liu, Hyunbum Jang and Ruth Nussinov

J. Chem. Theory Comput., 2023, 19, 1615
DOI: 10.1021/acs.jctc.2c01171

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement

Naiba Nabieva and Peter Fasching

Cancers, 2021, 13, 5643
DOI: 10.3390/cancers13225643

Direct K-Ras Inhibitors to Treat Cancers: Progress, New Insights, and Approaches to Treat Resistance

Ruth Nussinov and Hyunbum Jang

Annu. Rev. Pharmacol. Toxicol., 2024, 64, 231
DOI: 10.1146/annurev-pharmtox-022823-113946

Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric Carcinoma

Suparna Ghosh and Seung Joo Cho

Biomedicines, 2022, 10, 813
DOI: 10.3390/biomedicines10040813

Targeting the PI3K/AKT/mTOR Signaling Pathway in Lung Cancer: An Update Regarding Potential Drugs and Natural Products

Iksen, Sutthaorn Pothongsrisit and Varisa Pongrakhananon

Molecules, 2021, 26, 4100
DOI: 10.3390/molecules26134100

Outliers in SAR and QSAR: 4. effects of allosteric protein–ligand interactions on the classical quantitative structure–activity relationships

Ki Hwan Kim

Mol Divers, 2022, 26, 3057
DOI: 10.1007/s11030-021-10365-6

Case report: Novel PIK3CA and AXIN1 mutations in acinar cell carcinoma of the stomach arising from pancreatic heterotopia

Brian T Brinkerhoff, Mandy VanSandt, Skye C Mayo, Carol Beadling and Christopher L Corless

Human Pathology: Case Reports, 2021, 25, 200529
DOI: 10.1016/j.ehpc.2021.200529

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative

Liliana Ascione, Paola Zagami, Eleonora Nicolò, Edoardo Crimini, Giuseppe Curigliano and Carmen Criscitiello

JPM, 2022, 12, 1793
DOI: 10.3390/jpm12111793

Treating non-small cell lung cancer by targeting the PI3K signaling pathway

Lin Jiang, Jingbo Zhang, Yan Xu, Heng Xu and Mengzhao Wang

Chinese Medical Journal, 2022, 135, 1272
DOI: 10.1097/CM9.0000000000002195

Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein

John M. Ketcham, Stephen J. Harwood, Ruth Aranda, Athenea N. Aloiau, Briana M. Bobek, David M. Briere, Aaron C. Burns, Kersti Caddell Haatveit, Andrew Calinisan, Jeffery Clarine, Adam Elliott, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Benjamin Jones, Jon Kuehler, J. David Lawson, Natalie Nguyen, Cody Parker, Kelly E. Pearson, Lisa Rahbaek, Barbara Saechao, Xiaolun Wang, Anna Waters, Laura Waters, Ashlee H. Watkins, Peter Olson, Christopher R. Smith, James G. Christensen and Matthew A. Marx

J. Med. Chem., 2024, 67, 4936
DOI: 10.1021/acs.jmedchem.4c00078

Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements

Valéria Tavares, Inês Soares Marques, Inês Guerra de Melo, Joana Assis, Deolinda Pereira and Rui Medeiros

IJMS, 2024, 25, 1845
DOI: 10.3390/ijms25031845

Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα

Xiao Liu, Qingtong Zhou, Jonathan R. Hart, Yingna Xu, Su Yang, Dehua Yang, Peter K. Vogt and Ming-Wei Wang

Proc. Natl. Acad. Sci. U.S.A., 2022, 119
DOI: 10.1073/pnas.2215621119

Drugging multiple same-allele driver mutations in cancer

Ruth Nussinov, Mingzhen Zhang, Ryan Maloney and Hyunbum Jang

Expert Opinion on Drug Discovery, 2021, 16, 823
DOI: 10.1080/17460441.2021.1905628

Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition

Ruth Nussinov, Mingzhen Zhang, Chung-Jung Tsai and Hyunbum Jang

Molecular Cancer Research, 2021, 19, 543
DOI: 10.1158/1541-7786.MCR-20-0818

LncRNA SNHG1 targets miR‐340‐5p/PIK3CA axis to regulate microvascular endothelial cell proliferation, migration, and angiogenesis in DR

Fu‐Tao He, Xiao‐Lin Fu, Mo‐Han Li, Chun‐Yan Fu and Jian‐Zhi Chen

The Kaohsiung J of Med Scie, 2023, 39, 16
DOI: 10.1002/kjm2.12625

The PI3K/AKT Pathway Is Activated by HGF in NT2D1 Non-Seminoma Cells and Has a Role in the Modulation of Their Malignant Behavior

Luisa Gesualdi, Erica Leonetti, Alessandra Cucina, Bianca Maria Scicchitano, Silvia Sorrentino, Maria Grazia Tarsitano, Andrea Isidori, Mariano Bizzarri, Antonio Filippini, Anna Riccioli, Marcella Cammarota, Vincenzo Gigantino, Giulia Ricci and Angela Catizone

IJMS, 2020, 21, 8669
DOI: 10.3390/ijms21228669

Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)

Dima A. Sabbah, Rima Hajjo, Sanaa K. Bardaweel and Haizhen A. Zhong

Expert Opinion on Therapeutic Patents, 2024, 34, 141
DOI: 10.1080/13543776.2024.2338100